Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: A BENESCO Markov cost-effectiveness analysis

Clinical Drug Investigation

Volumn 29, Issue 10, 2009, Pages 655-665

  Annemans, Lieven ^a   Nackaerts, Kristiaan ^b   Bartsch, Pierre ^c   Prignot, Jacques ^d   Marbaix, Sophie ^e  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

^d UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^e PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; VARENICLINE;

ADULT; AGED; ARTICLE; BELGIUM; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DATA BASE; FEMALE; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; LIFESPAN; MALE; MORBIDITY; MORTALITY; NICOTINE REPLACEMENT THERAPY; PATIENT COUNSELING; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; QUALITY ADJUSTED LIFE YEAR; SMOKING CESSATION; TOBACCO DEPENDENCE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BELGIUM; BENZAZEPINES; BUPROPION; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; COUNSELING; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; NICOTINE; NICOTINIC AGONISTS; QUINOXALINES; RECURRENCE; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 69549118718     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11317730-000000000-00000     Document Type: Article

References (41)

1. Demarest S, Drieskens S, Gisle L, et al. Health interview survey, Belgium, 2004 [online]. Available from URL: http://www.iph.fgov.be/EPIDEMIO/ hisia/index.htm [Accessed 2007 Mar 1]
2. Federaal plan ter bestrijding van het tabaksgebruik, R. Demotte, 2003 [online]. Available from URL: http://www.rudydemotte.be/plannl.pdf [Accessed 2007 Mar 1]
3. Van den Bruel A, Cleemput I, Van Linden A, et al. Effectiviteit en kosten-effectiviteit van behandelingen voor rookstop. Brussel: Federaal Kenniscentrum voor de Gezondheidszorg (KCE), 2004 Juni. KCE Reports vol. 1A. Ref. PF04-26.02A [online]. Available from URL: http://www.kce.fgov.be [Accessed 2007 Apr 1]
4. Kiiskinen U, Vartiainen E, Puska P, et al. Smoking-related costs among 25 to 59 year-old males in a 19-year individual follow-up. Eur J Public Health 2002; 12: 145-151 (Pubitemid 34664151)
5. Feenstra TL, Hamberg-van Reenen HH, Hoogenveen RT, et al. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. Value Health 2005; 8: 178-190
6. Data on file, IMS, Belgium, 2007 Apr
7. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 56-63
8. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006; 296: 47-55
9. Russell MA, Stapleton JA, Feyerabend C, et al. Targeting heavy smokers in general practice: randomised controlled trial of transdermal nicotine patches. BMJ 1993; 306: 1308-1312 (Pubitemid 23136742)
10. Wu P, Wilson K, Dimoulas P, et al. Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health 2006; 6: 300
11. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007; CD006103
12. Wetter DW, Cofta-Gunn L, Fouladi RT, et al. Late relapse/sustained abstinence among former smokers: a longitudinal study. Prev Med 2004; 39: 1156-1163 (Pubitemid 39468630)
13. Krall EA, Garvey AJ, Garcia RI. Smoking relapse after 2 years of abstinence: findings from the VA Normative Aging Study. Nicotine Tob Res 2002; 4: 95-100
14. Orme ME, Hogue SL, Kennedy LM, et al. Development of the health and economic consequences of smoking interactive model. Tob Control 2001; 10: 55-61
15. Howard P, Knight Ch, Boler A, et al. Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model: application to a population of US adult smokers. Pharmacoeconomics 2008; 26 (6): 497-511 (Pubitemid 351704858)
16. Nationaal Instituut voor Statistiek [online]. Available from URL: http://statbel.fgov.be/home-nl.a [Accessed 2007Mar 1]
17. Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. RIVM, Bilthoven, 2006 [online]. Available from URL: http://www.nationaalkompas. nl [Accessed 2007 Mar 1]
18. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000; 284: 706-712
19. Cassino C, Ito K, Bader I, et al. Cigarette smoking and ozone-associated emergency department use for asthma by adults in New York City. Am J Respir Crit Care Med 1999 Jun; 159 (6): 1773-1779 (Pubitemid 29275041)
20. Silagy C, Lancaster T, Stead L, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2004; (3): CD000146
21. Foulds J, Burke M, Steinberg M, et al. Advances in pharmacotherapy for tobacco dependence. Expert Opin Emerg Drugs 2004; 9: 39-53
22. van Baal PH, Hoeymans N, Hoogenveen RT, et al. Disability weights for comorbidity and their influence on health-adjusted life expectancy. Popul Health Metr 2006; 4: 1 (Pubitemid 44144637)
23. Spencer M, Briggs AH, Grossman RF, et al. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics 2005; 23: 619-637 (Pubitemid 40994129)
24. Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58: 388-393 (Pubitemid 36560940)
25. Caekelbergh K, Spaepen E, Annemans L. Management of COPD in Belgium: a real life cost of illness [poster]. ISPOR 8th Annual European Congress; 2005 Nov 6-8; Florence
26. Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001; 19: 855-863
27. Slobbe LCJ, Kommer GJ, Smit JM, et al. Kosten van ziekten in Nederland 2003. RIVM, Bilthoven; 2006 [online]. Available from URL: http://www. kostenvanziekten.nl [Accessed 2006 Dec 1]
28. Hay JW, Sterling KL. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics 2005; 23: 133-141
29. TCT database [online]. Available from URL: https://tct.fgov.be [Accessed 2009 Aug 1]
30. Muls E, van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: comparison between Belgium and the United States of a projected risk model. Atherosclerosis 1998; 137 Suppl.: S111-6
31. Duncan PW, Lai SM, Keighley J. Defining post-stroke recovery: implications for design and interpretation of drug trials. Neuropharmacology 2000; 39: 835-841 (Pubitemid 30103686)
32. Tengs TO, Lin TH. A meta-analysis of quality-of-life estimates for stroke. Pharmacoeconomics 2003; 21: 191-200
33. Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation. Stroke 1998; 29: 1083-1091 (Pubitemid 28265459)
34. Szende A, Svensson K, Stahl E, et al. Psychometric and utility-based measures of health status of asthmatic patients with different disease control level. Pharmacoeconomics 2004; 22: 537-547 (Pubitemid 38858296)
35. Centre Belge d'Information Pharmacothérapeutique (CBIP-BCFI) [online]. Available from URL: http://www.cbip.be [Accessed 2009 Aug 1]
36. Institut national d'assurance maladie-invalidité (RIZIV - INAMI) [online]. Available from URL: http://www.riziv.fgov.be [Accessed 2009 Aug 1]
37. Cleemput I, Van Wilder P, Vrijens F, et al. Richtlijnen voor farmaco-economisch onderzoek in België. Brussel: KCE Reports, 2008: 78B
38. Neyt M, Huybrechts M, Hulstaert F, et al. Trastuzumab in early stage breast cancer: a cost-effectiveness analysis for Belgium. Health Policy 2008; 87: 146-159
39. Tonstad S, Davies S, Flammer M, et al. Incidence of depression in randomized, double-blind, placebo-controlled varenicline clinical trials [poster]. 10th Annual Conference of the Society for Research on Nicotine and Tobacco (SRNT) Europe; 2008 Sep 23-26; Rome
40. Russ C, Davies S, Flammer M, et al. Incidence of psychiatric adverse events other than depression in randomized, double-blind, placebo-controlled varenicline clinical trials [poster]. 10th Annual Conference of the Society for Research on Nicotine and Tobacco (SRNT) Europe; 2008 Sep 23-26; Rome
41. Jackson II KC, Nahoopii R, Said Q, et al. An employer-based cost-benefit analysis of a novel pharmacotherapy agent for smoking cessation. J Occup Environ Med 2007; 49: 453-460 (Pubitemid 46624363)